American Chemical Society
jm5b01330_si_002.csv (1.42 kB)

Phenyl Ether- and Aniline-Containing 2‑Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase

Download (1.42 kB)
posted on 2015-11-12, 00:00 authored by Maris A. Cinelli, Huiying Li, Anthony V. Pensa, Soosung Kang, Linda J. Roman, Pavel Martásek, Thomas L. Poulos, Richard B. Silverman
Excess nitric oxide (NO) produced by neuronal nitric oxide synthase (nNOS) is implicated in neurodegenerative disorders. As a result, inhibition of nNOS and reduction of NO levels is desirable therapeutically, but many nNOS inhibitors are poorly bioavailable. Promising members of our previously reported 2-aminoquinoline class of nNOS inhibitors, although orally bioavailable and brain-penetrant, suffer from unfavorable off-target binding to other CNS receptors, and they resemble known promiscuous binders. Rearranged phenyl ether- and aniline-linked 2-aminoquinoline derivatives were therefore designed to (a) disrupt the promiscuous binding pharmacophore and diminish off-target interactions and (b) preserve potency, isoform selectivity, and cell permeability. A series of these compounds was synthesized and tested against purified nNOS, endothelial NOS (eNOS), and inducible NOS (iNOS) enzymes. One compound, 20, displayed high potency, selectivity, and good human nNOS inhibition, and retained some permeability in a Caco-2 assay. Most promisingly, CNS receptor counterscreening revealed that this rearranged scaffold significantly reduces off-target binding.